Moffitt Cancer Center announced today a collaboration with NVIDIA, Oracle and Deloitte* on an initiative aimed at revolutionizing cancer care delivery through advanced artificial intelligence and machine learning technologies.
An international interdisciplinary team of researchers, including Moffitt Cancer Center’s Tiffany Carson, Ph.D., has been selected to receive a Cancer Grand Challenges award.
Alex Jaeger, Ph.D., assistant member of the Molecular Oncology Department at Moffitt Cancer Center, has received a Damon Runyon-Rachleff Innovation Award. He is the first researcher in Florida and at Moffitt to earn this prestigious grant.
In a mini-review published in Cancer Epidemiology, Biomarkers & Prevention, a journal from the American Association for Cancer Research, Moffitt Cancer Center researchers shed light on the significant gaps in understanding and addressing the effects of hurricanes and extreme weather events on biological, psychosocial and clinical outcomes among cancer survivors.
A first-of-its-kind cellular immunotherapy pioneered at Moffitt Cancer Center has received approval from the Food and Drug Administration and is now available for patients with advanced melanoma. Lifileucel is the first tumor-infiltrating lymphocyte therapy, or TIL, approved for solid tumors.
In a new article published in the Journal of the National Cancer Institute, Moffitt Cancer Center researchers share data on the efficacy and safety of neoadjuvant chemotherapy for locally advanced penile squamous cell carcinoma, addressing a critical gap in evidence regarding treatment options for this rare and aggressive cancer.
In a new article published in the Journal of Clinical Oncology, Moffitt Cancer Center researchers in collaboration with Sylvester Comprehensive Cancer Center and groups around the world share results from a novel model that can provide tailored predictions of how individual patients respond to different therapies.
In a recent study published in eClinicalMedicine, part of The Lancet Discovery Science, Moffitt Cancer Center researchers demonstrate that there is a significant unmet need for improved analyses and reporting of patient-reported outcomes in genitourinary cancer clinical trials.
In a new article published in Nature Chemistry, Moffitt Cancer Center researchers describe their development of a new reagent that allows a more efficient approach to make sulfoximines, sulfonimidoyl fluorides and sulfonimidamides that may be used in medicines.
Axi-cel CAR T targets the CD19 molecule on large B-cell lymphoma cells. The ZUMA-7 trial demonstrated that axi-cel reduced the risk of disease progression, the need for new therapy, or death by 60% compared to standard therapy. Despite these positive outcomes in event-free survival and overall survival, some patients did not respond well to therapy or relapsed quickly after treatment. Researchers wanted to assess if there were specific tumor characteristics associated with improved outcomes that could better inform treatment selection. Their findings were published today in Nature Medicine.
In a recent article published in Nature Communications, Moffitt Cancer Center researchers, in collaboration with The Tisch Cancer Institute; St. Jude Children’s Research Hospital; the Agency for Science, Technology and Research in Singapore; and the University of Otago in New Zealand, demonstrate that deregulation of a protein called RBFOX2, involved in RNA splicing, contributes to the progression and metastasis of pancreatic cancer.
While scientists have made significant progress in understanding the molecular mechanisms leading to melanoma development, it is still unclear how the PTEN protein regulates melanoma progression. In a new study published in Cancer Research, a journal of the American Association for Cancer Research, Moffitt Cancer Center researchers reveal how the antitumor activity of PTEN suppresses the cancer-promoting activity of the FRA1 transcription factor through the AKT signaling pathway.
Moffitt Cancer Center researchers are working to better understand the molecular mechanisms that promote the development and progression of breast cancer brain metastasis to help improve diagnostics and treatments. In a new study published in the December issue of Cell Reports, they report on identifying a cell signaling pathway that controls breast cancer brain metastasis.
In a new study published in the Journal for ImmunoTherapy of Cancer, a team of researchers from the Donald A. Adam Melanoma and Skin Cancer Center of Excellence at Moffitt Cancer Center reveals differences in the mechanisms of action of two FDA-approved immune checkpoint inhibitor combination therapies for advanced melanoma.
Moffitt Cancer Center has received a $3.6 million grant from the National Institute of Dental and Craniofacial Research (U01DE033329) to further groundbreaking research that has unveiled a promising noninvasive diagnostic biomarker panel for the early detection of oropharyngeal cancer.
Researchers in Moffitt Cancer Center’s Donald A. Adam Melanoma and Skin Cancer Center of Excellence have been working to better understand what drives melanoma brain metastasis.
In a new study published in Cell Chemical Biology, Moffitt Cancer Center researchers demonstrate this, showing that the ROS1 inhibitor lorlatinib has activity against an additional protein called PYK2. The team also reveals the mechanisms of this inhibition.
In a new article published today in Science Translational Medicine, a team of Moffitt Cancer Center researchers, in collaboration with NFlection Therapeutics and researchers at Stanford University, reports the identification of a new drug, NFX-179, that can be applied to the skin and was shown to prevent the development of cutaneous squamous cell carcinoma in pre-clinical models.
The Center of Excellence for Evolutionary Therapy at Moffitt Cancer Center has received a $10.4 million grant to study the eco-evolutionary dynamics responsible for non-small cell lung cancer growth and treatment resistance.
Moffitt Cancer Center has been awarded a four-year, $3 million grant from the Department of Defense’s Congressionally Directed Medical Research Programs to develop new treatments for rare melanomas, including uveal melanoma. The grant will fund two projects aimed at advancing targeted alpha-particle therapies.
The Center for Immunization and Infection Research in Cancer at Moffitt Cancer Center is expanding its viral infection research in Africa. The cancer center has received a $5.5 million, five-year specialized research center grant (U54CA277834) from the National Cancer Institute to investigate virus-associated tumors that disproportionately impact men and women living with HIV in sub-Saharan Africa.
In a new study published and included on the cover of the journal Cancer Research, Moffitt Cancer Center researchers demonstrate how mathematical modeling combined with dynamic biomarkers can be used to characterize metastatic disease and identify appropriate therapeutic approaches to improve patient outcomes.
The Food and Drug Administration announced yesterday the approval of HEPZATO Kit to treat ocular melanoma that has spread to the liver. HEPZATO uses a hepatic delivery system to inject the chemotherapy drug melphalan into the liver, a procedure referred to as percutaneous hepatic perfusion (PHP). Moffitt Cancer Center’s Jonathan S. Zager, M.D., was the lead international principal investigator on the multinational FOCUS phase 3 clinical trial to test the procedure, which is manufactured by Delcath Systems, Inc.
A Moffitt Cancer Center researcher, in collaboration with investigators at the National Institutes of Health, are working to answer that question for the nearly 4 million breast cancer survivors in the United States. In their newest study, they found that compared to cancer-free women, breast cancer survivors experience a faster rate of aging.
Moffitt Cancer Center has named Brian D. Gonzalez, Ph.D., as the inaugural associate center director of Research Diversity and Workforce Development. In the new role, Gonzalez will lead efforts to increase diversity among Moffitt’s research faculty, staff and trainees, working in collaboration with the offices of Enterprise Equity; Community Outreach, Engagement & Equity; and Research Education & Training. He will also develop and implement the cancer center’s Plan to Enhance Diversity. This initiative is a new requirement from the National Cancer Institute to show that the workforce of an NCI-designated cancer center reflects the populations of the communities that it serves.
Moffitt Cancer Center researchers having been investigating what may trigger treatment related symptoms in patients with gynecologic cancers. In a new study published in the journal Cancers, they evaluated the relationship between inflammatory biomarkers and self-reported treatment related symptoms among this patient population.
Moffitt Cancer Center has launched the Department of Bioengineering. The new academic research department will be housed within the Division of Basic Science and led by W. Gregory Sawyer, Ph.D. Bioengineering integrates the disciplines of engineering and cancer biology.
Prostate cancer frequently metastasizes to the bone and is incurable. Moffitt Cancer Center researchers are working to identify new treatment options for this subset of patients. In a new article published today in Science Advances, a team of Moffitt scientists demonstrates that chimeric antigen receptor T-cell (CAR T) therapy is an effective antitumor approach in mouse models of bone metastatic prostate cancer.
Outcomes for patients with clear cell renal cell carcinoma have improved over the past decade due to the approval of immunotherapies, yet still there is a subset of patients who do not respond to this type of therapy. Moffitt Cancer Center researchers have been working to better understand how the immune cell microenvironment contributes to patient outcomes in hopes of identifying biomarkers that predict responses to treatment.
In a new article in Blood Cancer Discovery, which was published simultaneously with a presentation at the American Association for Cancer Research annual meeting 2023, a team of Moffitt Cancer Center researchers demonstrated a possible alternative approach. They showed that MYC activates a downstream pathway that chemically modifies a protein called eIF5A, and that inhibition of this modification process prevents lymphoma development and progression in mouse models.
Moffitt Cancer Center and Sylvester Comprehensive Cancer Center, part of UHealth — University of Miami Health System and the University of Miami Miller School of Medicine, are teaming up to increase cancer screening and prevention education throughout the state. The two institutions will be funding community implementation grants for members of the Florida Regional Cancer Control Collaborative.
Issam El Naqa, Ph.D., chair of Moffitt Cancer Center’s Machine Learning Department, has being inducted into the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows.
Immunotherapies have greatly improved the outcomes of many patients with melanoma. But there is still a need for new approaches for the subset of patients who do not respond well to this type of therapy. Moffitt Cancer Center researchers are looking at new targets to help inhibit tumor development and promote antitumor immunity, one being the STING signaling pathway. In a new article published in Nature Communications, a team of Moffitt and University of Miami Miller School of Medicine investigators demonstrate that targeting the STING pathway with a combination strategy results in improved antitumor activity.
In a new study published in the Journal of Clinical Oncology, Moffitt Cancer Center researchers report that a new smoking cessation intervention increased the number of patients who quit smoking compared to standard cessation approaches.
In a new study published in Nature Medicine, Moffitt Cancer Center physician-scientists, in collaboration with four cancer centers in the United States and Germany, reveal how microorganisms in the gut influence non-Hodgkin lymphoma patient outcomes to a type of cellular immunotherapy called chimeric antigen receptor T-cell therapy, or CAR T.
In a new article published today in the Journal of Clinical Oncology, Moffitt Cancer Center physician-scientists, in collaboration with institutions from across the United States and the United Kingdom, share promising phase 1b trial results of a new combination therapy — magrolimab + azacitidine — for patients with higher-risk MDS.
A team of researchers from institutions across the United States, including Moffitt Cancer Center, launched a phase 2 clinical trial evaluating a new treatment option for this patient population. Their results, published in The New England Journal of Medicine, show that treating resectable stage 3 and 4 melanoma patients with the immunotherapy drug pembrolizumab both before and after surgery greatly improves outcomes when compared to pembrolizumab given only after surgery.
In a new study published in the journal Cancer Immunology Research, our researchers, led by Amer A. Beg, Ph.D., show how stimulating dendritic cells through the CD40 and interferon β (IFNβ) pathways produces strong T cell activity against tumors and works in conjunction with immune checkpoint inhibitors to produce even stronger responses. The article also shares promising early results from a phase 1 clinical study of an oncolytic virus (MEM-288) that activates these pathways in patients with non-small cell lung cancer.
Not for public release
This news release is embargoed until 9-Feb-2023 11:00 AM EST
Released to reporters: 6-Feb-2023 12:10 PM EST
A reporter's PressPass is required to
access this story until the embargo expires on 9-Feb-2023 11:00 AM EST
The Newswise PressPass gives verified journalists access to embargoed stories.
Please log in to complete a presspass application.
If you have not yet registered, please Register. When you
fill out the registration form, please identify yourself as a reporter in order to
advance to the presspass application form.
Researchers at Moffitt Cancer Center are investigating new treatment approaches for this patient population. In a new article published in the International Journal of Radiation Oncology, Biology and Physics, our team of physicians, led by Daniel Oliver, M.D., and Stephen Rosenberg, M.D., shows that stereotactic body radiotherapy, or SBRT, is an effective treatment for patients with early stage lung neuroendocrine tumors.
Moffitt Cancer Center, Weill Cornell Medicine and the University of North Carolina School of Medicine have received a $3.5 million, five-year grant from the National Cancer Institute (NCI) to improve screening and preventative treatment of cervical cancer for women living with HIV in low-resource countries.
Not for public release
This news release is embargoed until 23-Jan-2023 11:00 AM EST
Released to reporters: 23-Jan-2023 9:30 AM EST
A reporter's PressPass is required to
access this story until the embargo expires on 23-Jan-2023 11:00 AM EST
The Newswise PressPass gives verified journalists access to embargoed stories.
Please log in to complete a presspass application.
If you have not yet registered, please Register. When you
fill out the registration form, please identify yourself as a reporter in order to
advance to the presspass application form.
Moffitt Cancer Center researchers have developed a tool to determine how a new class of prostate cancer therapies called radionuclide therapy (RNT) impacts patient-reported outcomes with the goal of using this information to guide treatment and improve quality of care. Their findings have been published in The Journal of Nuclear Medicine.
Moffitt Cancer Center researchers are working to develop smoking cessation tools and improve access for Spanish-speaking smokers. In a new article published in Annals of Family Medicine, Moffitt researchers report that proactively connecting Spanish-speaking patients with tobacco treatment delivered by state Quitlines leads to dramatic improvements in treatment enrollment and smoking cessation outcomes.
Moffitt Cancer Center researchers wanted to determine how PERK activity impacts the clinical outcomes of patients with melanoma. Their results are published in a new article in Cancer Cell.
Moffitt Cancer Center’s efforts to increase minority accrual to cancer treatment trials got a boost from the National Cancer Institute’s Connecting Underrepresented Populations to Clinical Trials U01 Grants Program. The five-year, $3.7 million grant will help the cancer center develop new digital tools and community outreach strategies to reach Black and Hispanic cancer patients and physicians in the Tampa Bay community.
In a new study published online ahead of print in the journal Vaccine, Moffitt Cancer Center researchers identify factors associated with high and low COVID-19 vaccine acceptance among cancer patients.